CADTH

CADTH REIMBURSEMENT REVIEW

Stakeholder Feedback on Draft Recommendation

TRIENTINE HYDROCHLORIDE (MAR-Trientine)

(Marcan Pharmaceuticals Inc.)

Indication: For the treatment of patients with Wilson's Disease who are intolerant to penicillamine.

October 28, 2021

CADTH

CADTH Reimbursement Review

Feedback on Draft Recommendation

Stakeholder information	
CADTH project number	SR0680
Name of the drug and Indication(s)	MAR-Trientine for the treatment of patients with Wilson's Disease who are intolerant to penicillamine
Organization Providing Feedback	FWG

1. Recommendation revisions Please indicate if the stakeholder requires the expert review committee to reconsider or clarify its recommendation.		
Request for Reconsideration	**Major revisions:** A change in recommendation **category** or patient **population** is requested	☐
	Minor revisions: A change in reimbursement **conditions** is requested	☐
No Request for Reconsideration	**Editorial revisions:** Clarifications in recommendation **text** are requested	X
	No requested revisions	☐

2. Change in recommendation category or conditions Complete this section if major or minor revisions are requested
Please identify the specific text from the recommendation and provide a rationale for requesting a change in recommendation.

3. Clarity of the recommendation Complete this section if editorial revisions are requested for the following elements
a) Recommendation rationale
Please provide details regarding the information that requires clarification.
b) Reimbursement conditions and related reasons
Drug plans may not be able to implement different prescribing conditions for pediatric and adult patients with respect to prescriber type. In addition, it may be difficult for drug plans to assess requests by different prescriber type at initiation and renewal.

c) Implementation guidance
Can CDEC and/or clinical experts comment on the appropriateness of using MAR-Trientine in patients who fail or have a contraindication (e.g., pregnant women) to d-penicillamine? Can CDEC and/or clinical experts comment on how drug plans should handle requests for patients less than 5 years of age if there are no other alternatives?

Outstanding Implementation Issues

In the event of a positive draft recommendation, drug programs can request further implementation support from CADTH on topics that cannot be addressed in the reimbursement review (e.g., concerning other drugs, without sufficient evidence to support a recommendation, etc.). Note that outstanding implementation questions can also be posed to the expert committee in Feedback section 4c.

Algorithm and implementation questions
1. Please specify sequencing questions or issues that should be addressed by CADTH (oncology only)
1. 2.
2. Please specify other implementation questions or issues that should be addressed by CADTH
1. 2.
Support strategy
3. Do you have any preferences or suggestions on how CADTH should address these issues?
May include implementation advice panel, evidence review, provisional algorithm (oncology), etc.